Novartis Ag

Ciba-geigy Corporation

Other

Marc Gerspacher

Robert Mah

Andreas Von Sprecher

Pascal Furet

Robin Alec Fairhurst

Sven Weiler

Silvio Roggo

Stefan Stutz

Alfred Sallmann

Andrea Vaupel

Walter Schilling

Catherine Leblanc

Philipp Holzer

Christoph Gaul

Silvio Ofner

Eva Altmann

Edwige Liliane Jeanne Lorthiois

Eric Vangrevelinghe

Siem J Veenstra

Johanne Renaud

Rainer Wilcken

Rolf Schurter

Bo Tong Liu

Rainer Machauer

Yves Auberson

Pascal Rigollier

Leo Widler

Christophe Mura

Rene Beerli

Claudia Betschart

Andreas Beck

Simona Cotesta

Carole Pissot Soldermann

Bo Liu

Christine Fritsch

Jürgen Hans-Hermann Hinrichs

Cristina Montserrat Nieto-Oberhuber

Alfred Sallman

Jean-Baptiste Georges Armand Langlois

Milen Todorov

Nicolas Warin

Carole Pissot Sondermann

Tengfei Li

Nadine Schneider

The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease.

Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use

The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

Pyrazolyl derivatives useful as anti-cancer agents

The invention relates to 2,7-disubstituted benzoxazole and 2,4-disubstituted oxazolo[5,4-c]pyridine compounds of the formula I given below, as well as salts thereof, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, these compounds for use in the treatment (including prophylaxis) of the animal, especially human, body (especially with regard to a proliferative disease), the use thereof&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;for the treatment especially of a protein tyrosine kinase mediated disease (such as a tumor disease) or for the manufacture of a pharmaceutical preparation for use in the treatment of such a disease, a method for the treatment of such a disease and a pharmaceutical preparation for the treatment of a disease as mentioned. The compounds are of the formula I, wherein the symbols are as defined in the description. The compounds inhibit, for example, JAK2 and JAK3.

Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors

A compound of formula (1): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 

Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives

The invention relates to compounds of formula I and salts thereof wherein the substituens are as defined in the specification, processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.

Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors

The present invention relates to compounds of formula I and salts thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameliorated by inhibition of phosphatidylinositol 3-kinase.

2-carboxamide cycloamino ureas

Substituted 2-carboxamide cycloamino ureas

The present invention relates to quinoxaline compound of the formula (I): wherein

Quinoxaline derivatives as tyrosine kinase activity inhibitors

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein R1-R7 are as disclosed in the specification.

Benzimidazole derivatives

A compound of formula (I): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 

Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives

Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists

1-aryl-2-acylamino-ethane compounds and their use as neurokinin

Compounds of formula I ##STR1## wherein rings A and B are as defined in the specification, have valuable pharmacological properties and are particularly effective as NK1 antagonists and substance P antagonists. Said compounds are prepared in a manner known per se.

Chromone Derivatives

Compounds of formula I ##STR1## wherein R.sub.1 -R.sub.5, X, Ar and Y are as defined in the description, have valuable pharmaceutical properties and are especially effective as leukotriene antagonists. They are prepared in a manner known per se.

Quinoline compound

The invention relates to a novel process for the preparation of compounds of formula I ##STR1## wherein R is straight-chain C.sub.2 -C.sub.4 alk-1-en-1-yl, and salts thereof, and to a novel starting material and the use thereof.

Process for the preparation of substituted indoles

Growing community of inventors

Basel, Switzerland

Marc Gerspacher